Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy

被引:6
|
作者
Lebret, Thierry [1 ]
Bouregba, Alain [1 ]
机构
[1] Hop Foch, Dept Urol, F-92151 Suresnes, France
关键词
prostate cancer; hormonal therapy; LHRH agonist; professional-patient relations; multidisciplinary care; nurse-led services;
D O I
10.1111/j.1464-410X.2008.07785.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To establish the roles of the urologist, general practitioner (GP) and nurse from the perspective of the patient with prostate cancer receiving hormone therapy, and to assess patient satisfaction, in particular with management and information needs. PATIENTS AND METHODS Patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue (LHRH-a) therapy were recruited by a representative sample of 58 French urologists (March to April 2007) and invited to complete a 42-item questionnaire. RESULTS In all, 350 representative patients participated in the study; > 90% were totally or quite satisfied with the information given by their urologist at diagnosis and the start of treatment. Their main contact during treatment was with the nurse who gave the injection (84% of patients). The nurse's main role was to provide clarity (60% of patients), guidance (35%) and support to the family (28%). Fewer patients discussed disease stage and progression with their nurse (29%) than with a doctor (urologist, 63%; or GP, 61%). Fewer also discussed treatment (24% vs 32%) but as many patients discussed the impact of their disease and treatment with their nurse as with their doctor (e.g. 33% discussed general health and fatigue with the nurse, vs 26% with the urologist). The need for contact with a health professional was greater during the early stages of treatment. Patients treated for < 12 months with 3-monthly injections were less likely to be in favour of spacing injections than patients treated for >= 3 years. CONCLUSION The patient consults the urologist for reliable information on disease and treatment, and to the GP for further support, if needed, but the nurse has the pivotal role. A 3-monthly injection schedule enables regular face-to-face contact between the nurse and the patient and their family, and contributes towards the patient's coping strategies and quality of life.
引用
收藏
页码:1419 / 1424
页数:6
相关论文
共 50 条
  • [41] Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients (vol 60, pg 399, 2008)
    Kaczmarek, Piotr
    Pokoca, Lech
    Niemirowicz, Jerzy
    Majewska, Ewa
    Baj, Zbigniew
    PHARMACOLOGICAL REPORTS, 2009, 61 (01) : 193 - 193
  • [42] Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer
    Weston, R
    Hussain, A
    George, E
    Parr, NJ
    BJU INTERNATIONAL, 2005, 95 (06) : 776 - 779
  • [43] Re: Cognitive Function in Patients with Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study Editorial Comment
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2018, 200 (02): : 222 - 222
  • [44] Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia
    Agarwal, DK
    Costello, AJ
    Peters, J
    Sikaris, K
    Crowe, H
    BJU INTERNATIONAL, 2000, 85 (06) : 690 - 695
  • [45] Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies
    Nyushko, K. M.
    Alekseev, B. Ya.
    Kalpinsky, A. S.
    Kaprin, A. D.
    ONKOUROLOGIYA, 2014, 10 (04): : 70 - 74
  • [46] Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
    Tisseverasinghe, Steven
    Tolba, Marwan
    Saad, Fred
    Gravis, Gwenaelle
    Bahoric, Boris
    Niazi, Tamim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4173 - +
  • [47] Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study
    Lebret, Thierry
    Davin, Jean-Louis
    Hennequin, Christophe
    Latorzeff, Igor
    Mignard, Jean-Pierre
    Moreau, Jean-Luc
    Rossi, Dominique
    Ruffion, Alain
    Zerbib, Marc
    Culine, Stephane
    THERAPEUTIC ADVANCES IN UROLOGY, 2014, 6 (06) : 205 - 214
  • [48] Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review
    Zhang, Xianlu
    Zhang, Gejun
    Wang, Jianfeng
    Wang, Yanli
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [49] Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer
    Curry, EA
    Sweeney, CJ
    JOURNAL OF UROLOGY, 2002, 168 (01): : 193 - 193
  • [50] HUMAN ANTI-LUTEINIZING HORMONE-RELEASING HORMONE ANTIBODIES IN PATIENTS TREATED WITH SYNTHETIC LUTEINIZING-HORMONE-RELEASING HORMONE
    MEAKIN, JL
    KEOGH, EJ
    MARTIN, CE
    FERTILITY AND STERILITY, 1985, 43 (05) : 811 - 813